# Tirzepatide moves more than half of treated teens below obesity threshold, new clinical trial reports

Source: [Medical Xpress - latest medical and health news stories](https://medicalxpress.com/news/2026-11-tirzepatide-teens-obesity-threshold-clinical.html) · 2026-11-17 · Medicine
Page: https://themorning.science/story/tirzepatide-moves-more-than-half-of-treated-teens-below-obesity-threshold-new-cl-33c6b7f68a03bf84
Kind: research · Impact: medium

## In brief

- Tirzepatide (Zepbound), a once-weekly injectable, acts on two gut hormone targets, GIP and GLP-1.
- A new clinical trial reports that more than half of treated teens moved below the obesity threshold.

## Why it matters

The trial suggests a dual-action drug can shift obesity status in adolescents, which is relevant to how pediatric obesity treatment is studied and managed.

## Coverage

- [Tirzepatide moves more than half of treated teens below obesity threshold, new clinical trial reports](https://medicalxpress.com/news/2026-11-tirzepatide-teens-obesity-threshold-clinical.html) — Medical Xpress - latest medical and health news stories, 2026-11-17

Tags: obesity, tirzepatide, pediatrics, clinical-trial, metabolism

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
